An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Anticancer Drugs
; 8(7): 657-61, 1997 Aug.
Article
in En
| MEDLINE
| ID: mdl-9311440
ABSTRACT
UNLABELLED Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. IN CONCLUSION:
paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Squamous Cell
/
Uterine Cervical Neoplasms
/
Paclitaxel
/
Antineoplastic Agents, Phytogenic
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Anticancer Drugs
Journal subject:
ANTINEOPLASICOS
Year:
1997
Document type:
Article
Affiliation country:
United States